The liver is responsible for more than 500 functions in the human body, including filtering harmful substances from the blood. Some people’s livers metabolize toxins more slowly than others, but too ...

May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical ...

Discover a study that suggests that dual therapy could offer a safer and more effective approach to treating MASLD.

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI oncological indications, today announced ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

High levels of liver enzymes in your blood may sometimes indicate an underlying liver condition that requires medical ...

A US study found a significantly higher cost of care associated with cirrhosis vs with heart failure or chronic obstructive pulmonary disease.

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

The Janus Henderson Global Life Sciences Fund returned 0.99% and the MSCI World Health Care IndexSM returned 5.10% for Q1 ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first ...

Researchers identified a rare variant on a single gene that appears to predispose patients to metabolic ...